8/12/2023 0 Comments Taurine dosage for schizophreniaAlthough he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1įirst, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282 320 patients, as with Bacloville), was negative (see Braillon et al2). Trial Registration: identifier: NCT00420823īaclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit The use of taurine warrants further investigation in larger randomized studies, particularly early in the course of psychosis. 006).Ĭonclusions: Adjunctive taurine did not improve cognition, but it appears to improve psychopathology in patients with first-episode psychosis. A significant group difference was found on one safety and tolerability item (psychic item 2, asthenia/lassitude/increased fatigability) of the Udvalg for Kliniske Undersogelser, with the taurine group showing a more favorable outcome (P =. There was no group difference in composite cognitive score (95% CI, −1.7 to 1.0 P =. 047) and Global Assessment of Functioning (95% CI, 0.3-8.8 P =. Additionally, improvements were observed in the Calgary Depression Scale for Schizophrenia (95% CI, 0.1-3.0 P =. Taurine significantly improved symptomatology measured by the BPRS total score (95% CI, 1.8-8.5 P =. Results: 86 participants (n = 47 taurine n = 39 placebo) were included in the final analysis. Secondary outcomes included tolerability and safety and additional clinical and functioning measures. The coprimary outcomes were change in symptomatology (measured by the Brief Psychiatric Rating Scale total score) and change in cognition (measured by the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery composite score) at 12 weeks. Patients taking low-dose antipsychotic medication were randomly assigned to receive once-daily taurine 4 g or placebo for 12 weeks. Methods: 121 patients with first-episode psychosis, aged 18-25 years, attending early intervention services consented to participate in this randomized, double-blind, placebo-controlled trial conducted from January 2007 to May 2009. The aim of this study was to determine the efficacy of adjunctive taurine in improving symptomatology and cognition among patients with a DSM-IV first-episode psychotic disorder. It also functions as a neuroprotective agent and has a role in neural development and neurogenesis. Objective: Taurine is an inhibitory neuromodulatory amino acid in the central nervous system that activates the GABA- and glycine-insensitive chloride channel and inhibits the N-methyl-d-aspartate receptor.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |